Next Article in Journal
The Role of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Predicting Complicated Appendicitis in Children
Previous Article in Journal
Delayed Traumatic Rupture of the Spleen in a Patient with Mantle Cell Non-Hodgkin Lymphoma after an In-Hospital Fall: A Fatal Case
Previous Article in Special Issue
Macular OCT’s Proficiency in Identifying Retrochiasmal Visual Pathway Lesions in Multiple Sclerosis—A Pilot Study
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Homonymous Hemiatrophy of Macular Ganglion Cell Layer as a Marker of Retrograde Neurodegeneration in Multiple Sclerosis—A Narrative Review

1
Medical Doctoral School, University of Oradea, 410087 Oradea, Romania
2
Department of Ophthalmology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
3
Department of Medical Informatics and Biostatistics, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania
4
Faculty of Medicine, “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
5
Department of Ophthalmology, County Emergency Hospital Cluj-Napoca, 400006 Cluj-Napoca, Romania
6
Department of Maxillo-Facial Surgery and Radiology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
*
Author to whom correspondence should be addressed.
Diagnostics 2024, 14(12), 1255; https://doi.org/10.3390/diagnostics14121255
Submission received: 28 April 2024 / Revised: 4 June 2024 / Accepted: 11 June 2024 / Published: 14 June 2024
(This article belongs to the Special Issue Advanced Role of Optical Coherence Tomography in Clinical Medicine)

Abstract

:
Retrograde axonal neurodegeneration along the visual pathway—either direct or trans-synaptic—has already been demonstrated in multiple sclerosis (MS), as well as in compressive, vascular, or posttraumatic lesions of the visual pathway. Optical coherence tomography (OCT) can noninvasively track macular and optic nerve changes occurring as a result of this phenomenon. Our paper aimed to review the existing literature regarding hemimacular atrophic changes in the ganglion cell layer identified using OCT examination in MS patients without prior history of optic neuritis. Homonymous hemimacular atrophy has been described in post-chiasmal MS lesions, even in patients with normal visual field results. Temporal and nasal macular OCT evaluation should be performed separately in all MS patients, in addition to an optic nerve OCT evaluation and a visual field exam.

1. Introduction

Multiple sclerosis (MS) is the most common inflammatory neurological disease in young adults with the average age of diagnosis around 30 years [1]. Multifocal demyelinating lesions affect both white and grey matter of the central nervous system (CNS) and can lead to irreversible neurological disability [2].
The 2017 McDonald criteria represent the current standard used for diagnosing MS [3]. The diagnosis is based on combined clinical-radiological findings proving the dissemination in time (DIT) and dissemination in space (DIS) of the lesions involving the CNS. DIS refers to detection of characteristic T2-hyperintense lesions observed using magnetic resonance imaging (MRI) in at least two out of four specified regions: periventricular, cortical or juxtacortical, infratentorial, and spinal cord. Additional laboratory examinations such as the testing of oligoclonal bands in cerebrospinal fluid can support MS diagnosis in patients with insufficient clinical or MRI evidence [3].

1.1. Visual Pathway Involvement in Multiple Sclerosis

MS demyelinating lesions can affect the afferent visual pathway at all anatomical sites starting from the optic nerve to the primary visual cortex [4]. The anterior visual system originates in the retinal ganglion cells. Their axons collectively compose the optic nerve, optic chiasm, and optic tract (OT), ultimately converging to the lateral geniculate nucleus (LGN) through synaptic connections. Axons of the next-level neurons originating in the LGN form the optic radiations (OR) which project onto the visual cortex; the retrogeniculate visual pathway is also referred to as the posterior visual pathway [5].
Lesions of the visual pathway can initiate the process of neurodegeneration toward the retina (retrograde degeneration) or the occipital cortex (anterograde degeneration). Moreover, trans-synaptic degeneration has been described in the human visual pathway and represents the transmission of neuronal damage effect beyond the LGN—i.e., the synaptic relay that connects the anterior and posterior visual pathways [5,6].
Optic neuritis is one of the most common presenting syndromes in MS [7]. In 2016, it was proposed that the optic nerve should be considered the fifth anatomical site of MS lesions in order to fulfil MRI criteria for DIS [8]. However, MRI, visual evoked potentials, and optical coherence tomography (OCT) are considered insufficient to support the diagnosis of MS in patients without a clear history or a clinical proof of optic neuritis [3].
Although rare, optic chiasmitis can also occur in MS, leading to bilateral visual loss that is either simultaneous or rapidly sequential, and a normal fundus in the initial stage, while the MRI examination usually demonstrates optic chiasm enhancement [9].
The damage of the OT in MS is poorly understood since these structures are not part of the classically evaluated sites for lesion dissemination [10,11]. Postmortem examinations presented by Plant et al. in 1992 revealed the lack of direct involvement of the OT in such patients [12]. However, subsequent autopsy studies investigating the presence of axonal damage at this level demonstrated a roughly 30% decrease in axonal density in MS patients, without obvious alteration of the cross-sectional appearance of the optic nerves [13]. Dasenbrock et al. emphasized that OT damage can appear in the absence of direct lesions, similarly to the optic nerve damage in the absence of optic neuritis [11]. Although direct OT lesions are rare in MS, studies reveal secondary damage at this level caused by either optic neuritis via anterograde degeneration, or higher lesions of the posterior visual pathway via retrograde trans-synaptic degeneration [11,14].
LGN volume loss in MS also occurs due to anterograde degeneration initiated from the retina, or retrograde degeneration from lesions involving the optic radiations [15].
Not only can retrogeniculate visual pathway damage occur, but the posterior visual pathway is also a preferentially affected area in MS [16]. Postmortem histopathological analyses along with MRI studies revealed that lesions of the OR are a common finding in MS patients [17,18]. The involvement of the OR is explained by their localization through the periventricular white matter, at which site MS lesions typically occur [11]. However, the secondary neurodegeneration of OR stemming from distant visual system impairment such as optic neuritis has also been described [5]. OR have a paramount role in the transmission of visual information to the primary visual cortex. Any damage at this level contributes in a great manner to the visual disability in MS [14,19,20].
Atrophy of the visual cortex has been described in individuals with MS with a history of optic neuritis, but typical MS lesions within the primary visual cortex have also been reported [5,16,21,22].

1.2. The Role of OCT in Tracking Neurodegeneration

Ocular OCT is a fast high-resolution imaging technique that can identify lesions localized at any level of the visual pathway by assessing the retinal neuronal damage at axonal (retinal nerve fiber layer) and/or cellular body (ganglion cell layer) level [23].
MS is associated with peripapillary retinal nerve fiber layer (pRNFL) thinning and macular ganglion cell (mGC) loss, with changes being greater in eyes with prior optic neuritis than in those with no history of such. Therefore, both OCT markers are recommended for the diagnosis and monitoring of MS, as well as for research purposes [24]. Of note, some papers report the OCT macular thickness of ganglion cell layer only (mGCL), while others present the combined thickness of ganglion cell layer plus inner plexiform layer (mGC-IPL), depending on the OCT machine employed.
The mechanism of retinal axonal atrophy and mGC loss in MS in the absence of optic neuritis remains unknown. Possible causative mechanisms are as follows: diffuse neurodegenerative processes, the presence of subclinical inflammation or chronic demyelination along the visual pathway, or retrograde trans-synaptic degeneration following lesions of the OR [5,25].
A retrochiasmal lesion can determine the atrophy of retinal ganglion cells that results in a homonymous hemimacular mGC loss on OCT, and corresponding homonymous visual field (VF) defects. The mGC changes appear earlier in the case of an OT lesion than in a retrogeniculate injury [26]. Mühlemann et al. reported that the homonymous hemiatrophy of mGC becomes discernible approximately 5 months following the onset of a retrochiasmal lesion [26]. The degree of mGC reduction in OR lesions varies notably among individuals and might reach its highest point within the initial two years post-injury [27].
In their study on retrogeniculate lesions linked to homonymous hemianopia, **dahra et al. observed that pRNFL thinning becomes apparent within the first few months [28]. This thinning worsens rapidly during the first 1–2 years, after which it tends to stabilize or progress slowly in the following years [28]. Additionally, the authors observed that visual recovery is likely to appear in the patients who experienced less pRNFL thinning in the first years [28]. The size of the lesion, but most importantly, its strategic localization (e.g., LGN), can have a paramount influence on the magnitude of trans-synaptic neurodegeneration [28].
Post-chiasmal retrograde degeneration presents some distinct features in clinical practice, such as the following: congruous mGC changes respecting the vertical midline, discrepancy between VF/mGC changes and pRNFL values, or the asymmetry of pRNFL (more evident in the superior-nasal and/or inferior-nasal sectors) [29]. Several studies showed that mGC evaluation is of greater importance in detecting retrograde trans-synaptic degeneration compared to pRNFL [26]. In contrast, pre-chiasmal neurodegeneration presents with incongruous changes in the mGC assessment that tend to respect the horizontal midline, lack of concordance between VF/mGC analysis and pRNFL, and a symmetrical pRNFL thinning pattern [29].
In the following sections of this paper, we will refer to post-chiasmal MS lesions.

2. Macular OCT Changes in MS

2.1. Homonymous Macular Hemiatrophy in MS

Several studies reported atrophic mGC changes respecting the vertical midline in patients with MS without a history of optic neuritis—Table 1 [30,31,32,33,34]. The majority of patients presented lesions involving the OR, with variable VF findings (Table 1).
Huang-Link et al. [30] reported in their article two cases of MS patients both showing a demyelinating lesion in the left OR related to a new clinical relapse. The OCT report of the first case showed left homonymous hemimacular mGC-IPL thinning along with pRNFL thinning, as well as a right homonymous hemianopia on VF test, corresponding to the left retrochiasmal lesion on brain MRI. The second case showed a progressive development of a nasal hemimacular mGCL atrophy and a slight thinning of pRNFL in the right eye along with normal VF, while the left eye showed generalized mGC loss corresponding to an older episode of optic neuritis.
Al-Louzi et al. [31] reported six RRMS cases with no prior optic neuritis, showing MRI lesions in different areas of the posterior visual pathway (such as LGN, OR, or visual cortex). This led to the development of homonymous mGC-IPL atrophy on OCT scans, with or without typical changes in homonymous hemianopia.
In their article, Lukewich et al. [32] presented seven patients, including four with demyelinating conditions (three of whom had MS) and three with traumatic brain injuries (TBI). Macular OCT examination revealed the homonymous hemiatrophy of mGC-IPL without significant VF impairment. Among patients with demyelinating conditions, lesions were observed at the OT level in three cases and at the LGN level in one case. Additionally, three of these patients experienced homonymous hemianopia, which resolved over time. In patients with TBI, no visible retrochiasmal lesions were observed on brain MRI.
In the study conducted by Ilardi et al. [33], 5 out of 135 patients with demyelinating diseases (MS, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody disease) showed homonymous hemimacular mGC-IPL atrophy, representing only 3.7% of the sample. Another pattern of mGC-IPL thinning involving a combination of hemimacular thinning in one eye and diffuse macular thinning in the other eye (“whole + half pattern”) was observed in 8.1% of the patients [33]. This pattern, particularly involving the nasal retina in the eye with the hemimacular thinning, may result from the chiasmal disease affecting all fibers of the optic nerve in one eye and the crossing fibers originating from the other eye. Among these 11 patients, 2 had a documented history of optic neuritis, while for the remaining patients, the authors could not determine whether the OCT findings were due to chiasmal involvement or optic nerve disease [33]. Most patients diagnosed with homonymous hemimacular atrophy exhibited demyelinating lesions in the post-geniculate visual pathway spread throughout both brain hemispheres, with the exception of one individual [33]. The “whole + half” aspect on macular OCT may likely be indicative of undetected or subclinical optic neuritis in one eye, compounded by a retrochiasmal lesion. Given the authors’ acknowledgment that their study was constrained by the inability to thoroughly evaluate the optic nerves, chiasm, and tracts on MRI, the accuracy of the reported percentage remains uncertain. Considering optic neuritis is a common manifestation of MS; it may have influenced the results, as many patients may not recognize mild episodes. Therefore, acknowledging the characteristic pattern of “homonymous hemiatrophy” associated with post-chiasmal lesions is crucial. The presence of homonymous hemiatrophy may be partially masked by a global loss of ganglion cells due to optic neuritis, potentially leading to an underestimation of its true prevalence, particularly given the rarity of chiasmal lesions in MS compared to the frequent occurrence of optic neuritis. In Figure 1, we present two MS patients with different macular GCL thinning patterns.
Schmutz and Borruat [34] conducted a retrospective study on MS patients with VF defects using automated static perimetry. Ten patients (50%) also underwent macular assessment, with OCT revealing homonymous mGCL thinning in three patients, diffuse unilateral or bilateral thinning of mGCL following previous optic neuritis in six patients, and normal mGCL thickness in one patient. Out of 20 patients included in the study, most had RRMS (90%). Homonymous VF defects (i.e, homonymous hemianopia, homonymous quadrantanopia, or homonymous scotoma) were the presenting symptoms in 35% of patients [34]. Sixty percent experienced complete recovery within a median time of 10 weeks. MRI showed lesions (located at the level of OR, OT, or LGN) explaining the VF defects in 7 out of 11 patients [34]. The authors also noted that homonymous hemiatrophy could occur due to either direct retrograde axonal degeneration or trans-synaptic retrograde axonal degeneration [34].

2.2. Relationship between OCT and VF

Retrochiasmal lesions most often lead to nonpersistent or even asymptomatic homonymous VF defects. It has been noted that in patients with MS, only large post-chiasmal lesions can lead to symptomatic homonymous VF defects [12].
Studies reveal that among patients presenting with homonymous VF defects, the hemiatrophy of mGC is found in 95% of those presenting pre-geniculate lesions, in comparison to only 64% of patients with retrogeniculate lesions [26].
Although rare, homonymous hemiatrophy of the mGCL in the absence of significant VF defects can be a hallmark of previous retrochiasmal lesions in MS patients, especially in those without obvious corresponding lesions on the MRI scan or a history of TBI [32].
The OCT evaluation of mGC can be a useful tool for the evaluation of DIT and DIS of MS characteristic lesions, as the homonymous hemiatrophy of mGC appears in more than 70% of all retrochiasmal damage [26,32]. Although homonymous hemiatrophy of mGC is more sensitive in detecting retrograde trans-synaptic degeneration than pRNFL assessment alone, and there are reports of mGC thinning associated with normal pRNFL values, it is recommended that both indicators be analyzed concurrently for the detection of retrochiasmal lesions [26]. The lack of specificity of pRNFL to detect sectoral neural loss seems to be attributed to the intricate arrangement of the nerve fibers around the optic disc [35].

3. Discussion

3.1. OCT Findings in MS

Kupersmith et al. [36] demonstrated that mGC-IPL is better than pRNFL in detecting early atrophy due to optic neuritis. The average pRNFL atrophy related to optic neuritis measured approximately 20 μm. Moreover, swelling of the optic disc may interfere and alter precise pRNFL assessments. mGC-IPL is a reliable biomarker for the detection of neurodegeneration in the visual pathway and can depict atrophy sooner than pRNFL. The mGC-IPL thinning can be detectable within 1 month post an acute episode of optic neuritis, whereas the detection of pRNFL changes may take up to 3 months [24].
Gabilondo et al. [37] studied retinal changes secondary to optic neuritis. They observed that optic neuritis-related macular atrophy was more severe and uniform at the level of internal sectors (i.e., surrounding the fovea) of the ETDRS grid, reflecting the mGC-IPL thinning. External sectors corresponding to the papillo-macular bundle presented more marked atrophy, mainly due to macular RNFL (mRNFL) thinning. Petzold at al. [38] did not recommend the use of mRNFL as a monitoring marker due to possible automated segmentation errors related to common ocular disorders (e.g., epiretinal membrane).
Irreversible damage to axons along the visual pathway can lead to retrograde trans-synaptic axonal degeneration, causing atrophy of the inner retinal layers [24]. This degeneration stops at the inner nuclear layer (INL)—the first bipolar neuron of the visual pathway—which acts as a barrier, thus making the INL of interest for the investigation of inflammation [24]. Gabilondo et al. [37] observed that INL thickness seems to thicken after an episode of optic neuritis. Balk et al. [39] also showed a link between increased INL volume, acute optic neuritis, and clinical relapses in MS eyes. Saidha et al. [40] reported the association of MS activity and a greater thickness of the combined INL and outer plexiform layer, while Knier et al. [41] observed a sustained INL thickness reduction after the use of disease modifying treatment. INL thickening can also be associated with the existence of microcystic macular oedema [42]. On the contrary, Green et al. [43] reported evident INL atrophy in non-acute progressive or longstanding MS eyes.
OCT-angiography (OCT-A) has been used to investigate the retinal vessel density and blood flow alterations in MS patients [44]. The observed retinal vessel density reduction in MS eyes may be due to inflammation of the optic nerve and retina, or neuroaxonal degeneration and thinning of retinal layers thickness [44]. A systematic review and meta-analysis of studies on MS patients using OCT-A concluded that MS eyes present a reduced vessel density in the superficial capillary plexus (SCP), deep capillary plexus, and radial peripapillary capillary plexus [44]. Notably, Murphy et al. [45] have shown a correlation between macular SCP vessel density and mGC-IPL thickness, particularly in MS-related optic neuritis eyes, indicating the importance of the SCP in supplying blood to the RNFL and mGC-IPL, as reported by Park et al. [46]. However, this meta-analysis did not show significant differences in macular SCP vessel density between MS eyes with and without optic neuritis [44]; therefore, OCT-A alone cannot be used as a marker to differentiate between optic neuritis and non-optic neuritis eyes.

3.2. OCT Parameters as an Outcome Measure in MS Clinical Trials

Although recent clinical trials included the OCT evaluation in the assessment of patients with different types of MS, to the best of our knowledge, there is no trial that investigated the hemimacular OCT changes respecting the vertical midline. In the STRIVE study [47], the only included OCT parameter was pRNFL. In the SPRINT-MS study [48], the investigated macular OCT parameters were the total macular volume and the mean mGC-IPL thickness. In the post hoc analysis of the same trial, the researchers investigated the average mGC-IPL thickness, as well as the average INL and outer nuclear layer thicknesses [49]. Another study included the mean values of pRNFL, mRNFL, and mGC-IPL thicknesses [50]. Moreover, the OCT results of only one eye per patient were considered [50].
By only including the average values of the retinal layers’ thicknesses in the analysis, a sectoral thinning such as hemimacular atrophy can be missed. We suggest that nasal and temporal macular sectors should be assessed separately as the retrograde neurodegeneration process initiated by retrochiasmal MS lesions can determine an asymmetrical macular alteration relative to the vertical midline. This idea is also supported by the results of the study conducted by Pérez del Palomar et al. [51], in which pRNFL, mRNFL, and mGC-IPL losses were compared between MS patients and healthy controls using different machine learning techniques. According to this research, the temporal area of the macula was highly significant to predict the disease [51].

3.3. Differences in OCT Protocols for the Evaluation of Retrochiasmal Lesions in MS

Although the combined analysis of pRNFL and mGC-IPL is recommended for the detection and monitoring of neurodegeneration secondary to post-chiasmal visual pathway lesions in MS [24], some papers have not provided complete data on both OCT markers. Moreover, some studies have used mGCL analysis alone, whereas others evaluated the GCL thickness in combination with the IPL layer [30,31,32,33,34].
For the macular analysis of patients with MS, the most frequently used scanning protocol has been the ETDRS grid with concentric circles [30,31,32,33,34]. Recently, there has been a transition to using a square grid for these examinations [52,53].

3.4. Homonymous Hemiatrophy of mGC in Other Disorders

The homonymous hemiatrophy of mGC is not specific to demyelinating etiology, but rather serves as a distinctive hallmark indicating the presence of retrograde degeneration in a spectrum of cerebral disorders such as those of vascular, tumoral, compressive, traumatic, inflammatory, or demyelinating origins.
Meier et al. [54] reported the presence of mGC thinning in retrogeniculate vascular, inflammatory, and compressive lesions. In their study, all patients had a homonymous hemiatrophy pattern of mGC loss that correlated well with the VF loss, but not with the pRNFL thickness [52]. However, the prediction of the extent of VF loss from mGC loss and vice versa was not readily achievable. The temporal characteristics for trans-synaptic retrograde degeneration remained indeterminate, as its occurrence was not consistently manifested in all individuals affected by retrogeniculate lesions [54].
Blanch et al. emphasized the importance of OCT macular assessment in patients with sellar tumors [55]. Despite normal or near normal VF results or pRNFL thickness, the mGC-IPL evaluation showed binasal loss or global mGC-IPL thinning, which demonstrates that mGC-IPL has the finest sensitivity in the detection of chiasmal compression [55]. The mGC-IPL changes can be detected as early as 3 to 4 weeks after the axonal injury, whereas pRNFL thinning can be identified 4 to 6 weeks post-injury [56].
The utility of mGC analysis in detecting retrograde degeneration is also supported by several other papers [26,57,58,59].

4. Future Directions

We suggest that the difference between nasal and temporal macular thicknesses (irrespective of the evaluated macular layer) should be investigated in MS patients compared to healthy controls and/or between various subtypes of MS. Moreover, both eyes of the patients should be included in the analysis. An asymmetry score between right-sided and left-sided hemimaculae could prove to be of benefit for the early detection of retrochiasmal MS lesions using OCT technology.

5. Conclusions

MS lesions can affect the entire afferent visual pathway, and a comprehensive ophthalmic evaluation of MS patients is mandatory even in the absence of symptoms of optic neuritis. The OCT evaluation of mGC thickness in addition to pRNFL thickness and VF evaluation is of paramount importance. Based on the available data in the literature, we suggest that not only should the average mGC thickness be assessed in MS patients, but also the nasal and temporal mGC thicknesses should be assessed, as hemimacular mGC atrophy can be the first sign of a retrochiasmal MS lesion.

Author Contributions

Conceptualization, L.C., A.B., C.S., T.D., A.-P.C., C.N.; Methodology, L.C., A.B., T.D., C.S., A.-P.C., C.A.C., C.N.; Writing—original draft preparation, L.C., A.B.; writing—review and editing, L.C., A.B., C.A.C.; Supervision, C.N., T.D., C.S. All authors have read and agreed to the published version of the manuscript.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Wallin, M.T.; Culpepper, W.J.; Nichols, E.; Bhutta, Z.A.; Gebrehiwot, T.T.; Hay, S.I.; Khalil, I.A.; Krohn, K.J.; Liang, X.; Naghavi, M.; et al. Global, regional, and national burden of multiple sclerosis 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019, 18, 269–285. [Google Scholar] [CrossRef] [PubMed]
  2. Travers, B.S.; Tsang, B.K.T.; Barton, J.L. Multiple sclerosis diagnosis, disease-modifying therapy and prognosis. Aust. J. Gen. Pract. 2022, 51, 199–206. [Google Scholar] [CrossRef] [PubMed]
  3. Thompson, A.J.; Banwell, B.L.; Barkhof, F.; Carroll, W.M.; Coetzee, T.; Comi, G.; Correale, J.; Fazekas, F.; Filippi, M.; Freedman, M.S.; et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018, 17, 162–173. [Google Scholar] [CrossRef] [PubMed]
  4. Gallo, A.; Bisecco, A.; Bonavita, S.; Tedeschi, G. Functional plasticity of the visual system in multiple sclerosis. Front. Neurol. 2015, 6, 79. [Google Scholar] [CrossRef] [PubMed]
  5. Gabilondo, I.; Martínez-Lapiscina, E.H.; Martínez-Heras, E.; Fraga-Pumar, E.; Llufriu, S.; Ortiz, S.; Bullich, S.; Sepulveda, M.; Falcon, C.; Berenguer, J.; et al. Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Ann. Neurol. 2014, 75, 98–107. [Google Scholar] [CrossRef] [PubMed]
  6. Dinkin, M. Trans-synaptic retrograde degeneration in the human visual system: Slow, silent, and real. Curr. Neurol. Neurosci. Rep. 2017, 17, 16. [Google Scholar] [CrossRef] [PubMed]
  7. Reich, D.S.; Lucchinetti, C.F.; Calabresi, P.A. Multiple Sclerosis. N. Engl. J. Med. 2018, 378, 169–180. [Google Scholar] [CrossRef] [PubMed]
  8. Filippi, M.; Rocca, M.A.; Ciccarelli, O.; De Stefano, N.; Evangelou, N.; Kappos, L.; Rovira, A.; Sastre-Garriga, J.; Tintorè, M.; Frederiksen, J.L.; et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016, 15, 292–303. [Google Scholar] [CrossRef]
  9. Cuna, A.; Pellegrini, F.; Interlandi, E.; Mandarà, E.; De Luca, M.; De Marco, R.; Ciabattoni, C.; Zappacosta, A.; Papayannis, A. Optical coherence tomography angiography in chiasmitis. Case Rep. Ophthalmol. 2022, 13, 517–522. [Google Scholar] [CrossRef]
  10. Rosenblatt, M.A.; Behrens, M.M.; Zweifach, P.H.; Forman, S.; Odel, J.G.; Duncan, C.M.; Gross, S.A. Magnetic resonance imaging of optic tract involvement in multiple sclerosis. Am. J. Ophthalmol. 1987, 104, 74–79. [Google Scholar] [CrossRef]
  11. Dasenbrock, H.H.; Smith, S.A.; Ozturk, A.; Farrell, S.K.; Calabresi, P.A.; Reich, D.S. Diffusion tensor imaging of the optic tracts in multiple sclerosis: Association with retinal thinning and visual disability. J. Neuroimaging 2011, 21, e41–e49. [Google Scholar] [CrossRef] [PubMed]
  12. Plant, G.T.; Kermode, A.G.; Turano, G.; Moseley, I.F.; Miller, D.H.; MacManus, D.G.; Halliday, A.M.; McDonald, W.I. Symptomatic retrochiasmal lesions in multiple sclerosis. Neurology 1992, 42, 68–76. [Google Scholar] [CrossRef] [PubMed]
  13. Kerrison, J.B.; Flynn, T.; Green, W.R. RETINAL PATHOLOGIC CHANGES IN MULTIPLE SCLEROSIS. Retina 1994, 14, 445–451. [Google Scholar] [CrossRef] [PubMed]
  14. Graham, S.L.; Klistorner, A. Afferent visual pathways in multiple sclerosis: A review. Clin. Exp. Ophthalmol. 2017, 45, 62–72. [Google Scholar] [CrossRef] [PubMed]
  15. Papadopoulou, A.; Gaetano, L.; Pfister, A.; Altermatt, A.; Tsagkas, C.; Morency, F.; Brandt, A.U.; Hardmeier, M.; Chakravarty, M.M.; Descoteaux, M.; et al. Damage of the lateral geniculate nucleus in MS. Neurology 2019, 92, e2240–e2249. [Google Scholar] [CrossRef] [PubMed]
  16. Castro, S.M.C.; Damasceno, A.; Damasceno, B.P.; de Vasconcellos, J.P.; Reis, F.; Iyeyasu, J.N.; de Carvalho, K.M. Visual pathway abnormalities were found in most multiple sclerosis patients despite history of previous optic neuritis. Arq. Neuro-Psiquiatr. 2013, 71, 437–441. [Google Scholar] [CrossRef] [PubMed]
  17. Brownell, B.; Hughes, J.T. The distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1962, 25, 315–320. [Google Scholar] [CrossRef] [PubMed]
  18. Hornabrook, R.S.; Miller, D.H.; Newton, M.R.; MacManus, D.G.; du Boulay, G.H.; Halliday, A.M.; McDonald, W.I. Frequent involvement of the optic radiation in patients with acute isolated optic neuritis. Neurology 1992, 42, 77. [Google Scholar] [CrossRef] [PubMed]
  19. Lennartsson, F.; Nilsson, M.; Flodmark, O.; Jacobson, L. Damage to the immature optic radiation causes severe reduction of the retinal nerve fiber layer, resulting in predictable visual field defects. Investig. Ophthalmol. Vis. Sci. 2014, 55, 8278–8288. [Google Scholar] [CrossRef]
  20. Reich, D.S.; Ozturk, A.; Calabresi, P.A.; Mori, S. Automated vs. conventional tractography in multiple sclerosis: Variability and correlation with disability. Neuroimage 2010, 49, 3047–3056. [Google Scholar] [CrossRef]
  21. Reich, D.S.; Smith, S.A.; Gordon-Lipkin, E.M.; Ozturk, A.; Caffo, B.S.; Balcer, L.J.; Calabresi, P.A. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch. Neurol. 2009, 66, 998–1006. [Google Scholar] [CrossRef]
  22. Rocca, M.A.; Mesaros, S.; Preziosa, P.; Pagani, E.; Stosic-Opincal, T.; Dujmovic-Basuroski, I.; Drulovic, J.; Filippi, M. Wallerian and trans-synaptic degeneration contribute to optic radiation damage in multiple sclerosis: A diffusion tensor MRI study. Mult. Scler. J. 2013, 19, 1610–1617. [Google Scholar] [CrossRef] [PubMed]
  23. Chen, J.J.; Costello, F. The role of optical coherence tomography in neuro-ophthalmology. Ann. Eye Sci. 2018, 3, 35. [Google Scholar] [CrossRef]
  24. Petzold, A.; Balcer, L.J.; Calabresi, P.A.; Costello, F.; Frohman, T.C.; Frohman, E.M.; Martinez-Lapiscina, E.H.; Green, A.J.; Kardon, R.; Outteryck, O.; et al. Retinal layer segmentation in multiple sclerosis: A systematic review and meta-analysis. Lancet Neurol. 2017, 16, 797–812. [Google Scholar] [CrossRef] [PubMed]
  25. Klistorner, A.; Sriram, P.; Vootakuru, N.; Wang, C.; Barnett, M.H.; Garrick, R.; Parratt, J.; Levin, N.; Raz, N.; Van der Walt, A.; et al. Axonal loss of retinal neurons in multiple sclerosis associated with optic radiation lesions. Neurology 2014, 82, 2165–2172. [Google Scholar] [CrossRef] [PubMed]
  26. Mühlemann, F.; Grabe, H.; Fok, A.; Wagner, F.; Brügger, D.; Sheldon, C.A.; Abegg, M. Homonymous hemiatrophy of ganglion cell layer from retrochiasmal lesions in the visual pathway. Neurology 2020, 94, e323–e329. [Google Scholar] [CrossRef] [PubMed]
  27. Donaldson, L.; Margolin, E. Visual fields and optical coherence tomography (OCT) in neuro-ophthalmology: Structure-function correlation. J. Neurol. Sci. 2021, 429, 118064. [Google Scholar] [CrossRef] [PubMed]
  28. **dahra, P.; Petrie, A.; Plant, G.T. The time course of retrograde trans-synaptic degeneration following occipital lobe damage in humans. Brain 2012, 135, 534–541. [Google Scholar] [CrossRef] [PubMed]
  29. Zangerl, B.; Whatham, A.; Kim, J.; Choi, A.; Assaad, N.N.; Hennessy, M.P.; Kalloniatis, M. Reconciling visual field defects and retinal nerve fibre layer asymmetric patterns in retrograde degeneration: An extended case series. Clin. Exp. Optom. 2017, 100, 214–226. [Google Scholar] [CrossRef]
  30. Huang-Link, Y.-M.; Al-Hawasi, A.; Eveman, I. Retrograde degeneration of visual pathway: Hemimacular thinning of retinal ganglion cell layer in progressive and active multiple sclerosis. J. Neurol. 2014, 261, 2453–2456. [Google Scholar] [CrossRef]
  31. Al-Louzi, O.; Button, J.; Newsome, S.D.; Calabresi, P.A.; Saidha, S. Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series. Mult. Scler. J. 2017, 23, 1035–1039. [Google Scholar] [CrossRef] [PubMed]
  32. Lukewich, M.K.; Schlenker, M.B.; Micieli, J.A. Homonymous hemi-macular atrophy of the ganglion cell-inner plexiform layer with preserved visual function. J. Neurol. Sci. 2020, 417, 117072. [Google Scholar] [CrossRef] [PubMed]
  33. Ilardi, M.; Nolan-Kenney, R.; Fatterpekar, G.; Hasanaj, L.; Serrano, L.; Joseph, B.; Wu, S.; Rucker, J.C.; Balcer, L.J.; Galetta, S.L. Role for OCT in detecting hemi-macular ganglion cell layer thinning in patients with multiple sclerosis and related demyelinating diseases. J. Neurol. Sci. 2020, 419, 117159. [Google Scholar] [CrossRef] [PubMed]
  34. Schmutz, L.; Borruat, F.-X. Homonymous visual field defects in patients with multiple sclerosis: Results of computerised perimetry and optical coherence tomography. Swiss Med. Wkly. 2020, 150, w20319. [Google Scholar] [CrossRef] [PubMed]
  35. Hokazono, K.; Ribeiro Monteiro, M.L. Homonymous quadrantic macular ganglion cell complex loss as a sign of trans-synaptic degeneration from occipital lobe lesion. Am. J. Ophthalmol. Case Rep. 2018, 13, 76–79. [Google Scholar] [CrossRef] [PubMed]
  36. Kupersmith, M.J.; Garvin, M.K.; Wang, J.-K.; Durbin, M.; Kardon, R. Retinal ganglion cell layer thinning within one month of presentation for optic neuritis. Mult. Scler. J. 2016, 22, 641–648. [Google Scholar] [CrossRef] [PubMed]
  37. Gabilondo, I.; Martínez-Lapiscina, E.H.; Fraga-Pumar, E.; Ortiz-Perez, S.; Torres-Torres, R.; Andorra, M.; Llufriu, S.; Zubizarreta, I.; Saiz, A.; Sanchez-Dalmau, B.; et al. Dynamics of retinal injury after acute optic neuritis. Ann. Neurol. 2015, 77, 517–528. [Google Scholar] [CrossRef] [PubMed]
  38. Petzold, A.; Chua, S.Y.L.; Khawaja, A.P.; Keane, P.A.; Khaw, P.T.; Reisman, C.; Dhillon, B.; Strouthidis, N.G.; Foster, P.J.; Patel, P.J.; et al. Retinal asymmetry in multiple sclerosis. Brain 2021, 144, 224–235. [Google Scholar] [CrossRef] [PubMed]
  39. Balk, L.J.; Coric, D.; Knier, B.; Zimmermann, H.G.; Behbehani, R.; Alroughani, R.; Martinez-Lapiscina, E.H.; Brandt, A.U.; Sánchez-Dalmau, B.; Vidal-Jordana, A.; et al. Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. Mult. Scler. J. Exp. Transl. Clin. 2019, 5, 2055217319871582. [Google Scholar] [CrossRef]
  40. Saidha, S.; Sotirchos, E.S.; Ibrahim, M.A.; Crainiceanu, C.M.; Gelfand, J.M.; Sepah, Y.J.; Ratchford, J.N.; Oh, J.; Seigo, M.A.; Newsome, S.D.; et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: A retrospective study. Lancet Neurol. 2012, 11, 963–972. [Google Scholar] [CrossRef]
  41. Knier, B.; Schmidt, P.; Aly, L.; Buck, D.; Berthele, A.; Mühlau, M.; Zimmer, C.; Hemmer, B.; Korn, T. Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis. Brain 2016, 139, 2855–2863. [Google Scholar] [CrossRef] [PubMed]
  42. Gelfand, J.M.; Nolan, R.; Schwartz, D.M.; Graves, J.; Green, A.J. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 2012, 135 Pt 6, 1786–1793. [Google Scholar] [CrossRef] [PubMed]
  43. Green, A.J.; McQuaid, S.; Hauser, S.L.; Allen, I.V.; Lyness, R. Ocular pathology in multiple sclerosis: Retinal atrophy and inflammation irrespective of disease duration. Brain 2010, 133 Pt 6, 1591–1601. [Google Scholar] [CrossRef] [PubMed]
  44. Mohammadi, S.; Gouravani, M.; Salehi, M.A.; Arevalo, J.F.; Galetta, S.L.; Harandi, H.; Frohman, E.M.; Frohman, T.C.; Saidha, S.; Sattarnezhad, N.; et al. Optical coherence tomography angiography measurements in multiple sclerosis: A systematic review and meta-analysis. J. Neuroinflamm. 2023, 20, 85. [Google Scholar] [CrossRef] [PubMed]
  45. Murphy, O.C.; Kwakyi, O.; Iftikhar, M.; Zafar, S.; Lambe, J.; Pellegrini, N.; Sotirchos, E.S.; Gonzalez-Caldito, N.; Ogbuokiri, E.; Filippatou, A.; et al. Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures. Mult. Scler. J. 2020, 26, 815–828. [Google Scholar] [CrossRef]
  46. Park, J.J.; Soetikno, B.T.; Fawzi, A.A. Characterization of the middle capillary plexus using optical coherence tomography angiography in healthy and diabetic eyes. Retina 2016, 36, 2039–2050. [Google Scholar] [CrossRef] [PubMed]
  47. Perumal, J.; Fox, R.J.; Balabanov, R.; Balcer, L.J.; Galetta, S.; Makh, S.; Santra, S.; Hotermans, C.; Lee, L. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: A prespecified 2-year interim analysis of STRIVE. BMC Neurol. 2019, 19, 116. [Google Scholar] [CrossRef] [PubMed]
  48. Bermel, R.A.; Fedler, J.K.; Kaiser, P.; Novalis, C.; Schneebaum, J.; Klingner, E.A.; Williams, D.; Yankey, J.W.; Ecklund, D.J.; Chase, M.; et al. Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis. Mult. Scler. J. 2021, 27, 1384–1390. [Google Scholar] [CrossRef] [PubMed]
  49. Ehrhardt, H.; Lambe, J.; Moussa, H.; Vasileiou, E.S.; Kalaitzidis, G.; Murphy, O.C.; Filippatou, A.G.; Pellegrini, N.; Douglas, M.; Davis, S.; et al. Effects of ibudilast on retinal atrophy in progressive multiple sclerosis subtypes: Post hoc analyses of the SPRINT-MS Trial. Neurology 2023, 101, E1014–E1024. [Google Scholar] [CrossRef]
  50. Ingwersen, J.; Masanneck, L.; Pawlitzki, M.; Samadzadeh, S.; Weise, M.; Aktas, O.; Meuth, S.G.; Albrecht, P. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials. Sci. Rep. 2023, 13, 15003. [Google Scholar] [CrossRef]
  51. Pérez Del Palomar, A.; Cegoñino, J.; Montolío, A.; Orduna, E.; Vilades, E.; Sebastián, B.; Pablo, L.E.; Garcia-Martin, E. Swept source optical coherence tomography to early detect multiple sclerosis disease. The use of machine learning techniques. PLoS ONE 2019, 14, e0216410. [Google Scholar] [CrossRef] [PubMed]
  52. Cujba, L.; Stan, C.; Samoila, O.; Drugan, T.; Benedec Cutas, A.; Nicula, C. Identifying Optical Coherence Tomography Markers for Multiple Sclerosis Diagnosis and Management. Diagnostics 2023, 13, 2077. [Google Scholar] [CrossRef]
  53. Viladés, E.; Cordón, B.; Pérez-Velilla, J.; Orduna, E.; Satue, M.; Polo, V.; Sebastian, B.; Larrosa, J.M.; Pablo, L.; García-Martin, E. Evaluation of multiple sclerosis severity using a new OCT tool. PLoS ONE 2023, 18, e0288581. [Google Scholar] [CrossRef]
  54. Meier, P.G.; Maeder, P.; Borruat, F.X. Transsynaptic Retrograde Degeneration: Clinical Evidence with Homonymous RGCL Loss on OCT. Klin. Monbl. Augenheilkd. 2016, 233, 396–398. [Google Scholar] [CrossRef]
  55. Blanch, R.J.; Micieli, J.A.; Oyesiku, N.M.; Newman, N.J.; Biousse, V. Optical coherence tomography retinal ganglion cell complex analysis for the detection of early chiasmal compression. Pituitary 2018, 21, 515–523. [Google Scholar] [CrossRef] [PubMed]
  56. Banc, A.; Biousse, V.; Newman, N.J.; Kedar, S. Ocular optical coherence tomography in the evaluation of sellar and parasellar masses: A review. Neurosurgery 2023, 92, 42–67. [Google Scholar] [CrossRef]
  57. Mitchell, J.R.; Oliveira, C.; Tsiouris, A.J.; Dinkin, M.J. Corresponding ganglion cell atrophy in patients with postgeniculate homonymous visual field loss. J. Neuro-Ophthalmol. 2015, 35, 353–359. [Google Scholar] [CrossRef]
  58. Yamashita, T.; Miki, A.; Goto, K.; Araki, S.; Takizawa, G.; Ieki, Y.; Kiryu, J.; Tabuchi, A.; Iguchi, Y.; Kimura, K.; et al. Evaluation of significance maps and the analysis of the longitudinal time course of the macular ganglion cell complex thicknesses in acquired occipital homonymous hemianopia using spectral-domain optical coherence tomography. Neuro-Ophthalmology 2019, 44, 236–245. [Google Scholar] [CrossRef] [PubMed]
  59. Keller, J.; Sánchez-Dalmau, B.F.; Villoslada, P. Lesions in the posterior visual pathway promote trans-synaptic degeneration of retinal ganglion cells. PLoS ONE 2014, 9, e97444. [Google Scholar] [CrossRef]
Figure 1. Spectralis SD-OCT (spectral domain optical coherence tomography) macular scans (Heidelberg Engineering, Heidelberg, Germany) using Posterior Pole Analysis. (A) Macular analysis shows nasal hemimacular GCL thinning in the RE and temporal hemimacular GCL thinning in LE (left homonymous hemiatrophy of the GCL). (B) Macular analysis shows combination of diffuse macular GCL thinning in RE and nasal hemimacular GCL thinning in the LE (“whole + half pattern”). GCL, ganglion cell layer; RE, right eye; LE, left eye.
Figure 1. Spectralis SD-OCT (spectral domain optical coherence tomography) macular scans (Heidelberg Engineering, Heidelberg, Germany) using Posterior Pole Analysis. (A) Macular analysis shows nasal hemimacular GCL thinning in the RE and temporal hemimacular GCL thinning in LE (left homonymous hemiatrophy of the GCL). (B) Macular analysis shows combination of diffuse macular GCL thinning in RE and nasal hemimacular GCL thinning in the LE (“whole + half pattern”). GCL, ganglion cell layer; RE, right eye; LE, left eye.
Diagnostics 14 01255 g001
Table 1. Summary of the studies reporting mGC hemiatrophy in MS.
Table 1. Summary of the studies reporting mGC hemiatrophy in MS.
Authors,
Year of Publication
Number of PatientsPrior
Episodes of Optic
Neuritis (Number of Eyes)
VF FindingsmGC
Thinning Pattern
pRNFL FindingsMRI Findings
Huang-Link et al., 2014 [30]Active MS: 20Right homonymous hemianopiaLeft homonymous mGC atrophyBilateral pRNFL thinning (most marked temporally)Demyelinating lesion in the left OR
1NormalRight eye: nasal mGC thinning
Left eye: diffusely thinned mGC
Slightly thinned pRNFL in the right eye and markedly thinned pRNFL in the left eye (most marked temporally)Demyelinating lesion in the left OR
Al-Louzi et al., 2017 [31]RRMS: 604 pts: homonymous hemianopia1 pt: left homonymous mGC loss
3 pts: right homonymous mGC reduction
2 pts: right homonymous mGC reduction
Not reported1 pt: left occipital white matter lesion
3 pts: right occipital white matter lesion
2 pts: right thalamic lesions
Lukewich et al., 2020 [32]Demyelinating disease: 4 (MS: 3)
TBI: 3
Not reportedNo significant defect at the time of evaluation4 pts: right homonymous mGC thinning
3 pts: left homonymous mGC thinning
Not reported3 pts: contralateral OT lesion
1 pt: LGN lesion
Ilardi et al., 2020 [33]RRMS: 4
NMO: 1
11 pt: history of homonymous hemianopia2 pts: right homonymous mGC thinning
3 pts: lef homonymous mGC thinning
Not reported3 pts: bilateral demyelinating lesions of the post-geniculate visual pathway
1 pt: lesion of the OR on the opposite expected site
1 pt: no visible demyelinating lesion
Schmutz and Borruat, 2020 [34]RRMS: 18
PPMS: 1
SPMS: 1
93 pts: homonymous VF defect
11 pts: homonymous quadrantanopia
2 pts: homonymous hemianopia
3 pts: homonymous thinning
6 pts: diffuse unilateral or bilateral thinning (resulting from previous episodes of optic neuritis)
1 pt: normal mGC thickness
Not reported7 pts: an MRI-defined lesion explaining the VF defects: 5 pts—OR lesion; 1 pt—OT lesion; 1 pt—LGN lesion
RRMS, relapsing–remitting MS; TBI, traumatic brain injury; NMO, neuromyelitis optica; PPMS, primary progressive MS; SPMS, secondary progressive MS; mGC, macular ganglion cell layer; MS, multiple sclerosis; pRNFL, peripapillary retinal nerve fiber layer; pt(s), patient(s); VF, visual field; OT, optic tract; LGN, lateral geniculate nucleus; OR, optic radiations.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Cujbă, L.; Banc, A.; Drugan, T.; Coadă, C.A.; Cristea, A.-P.; Stan, C.; Nicula, C. Homonymous Hemiatrophy of Macular Ganglion Cell Layer as a Marker of Retrograde Neurodegeneration in Multiple Sclerosis—A Narrative Review. Diagnostics 2024, 14, 1255. https://doi.org/10.3390/diagnostics14121255

AMA Style

Cujbă L, Banc A, Drugan T, Coadă CA, Cristea A-P, Stan C, Nicula C. Homonymous Hemiatrophy of Macular Ganglion Cell Layer as a Marker of Retrograde Neurodegeneration in Multiple Sclerosis—A Narrative Review. Diagnostics. 2024; 14(12):1255. https://doi.org/10.3390/diagnostics14121255

Chicago/Turabian Style

Cujbă, Larisa, Ana Banc, Tudor Drugan, Camelia Alexandra Coadă, Andreea-Petra Cristea, Cristina Stan, and Cristina Nicula. 2024. "Homonymous Hemiatrophy of Macular Ganglion Cell Layer as a Marker of Retrograde Neurodegeneration in Multiple Sclerosis—A Narrative Review" Diagnostics 14, no. 12: 1255. https://doi.org/10.3390/diagnostics14121255

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop